| Metric | Current | Prior | YoY |
|---|---|---|---|
| Revenue | ¥155.3B | ¥152.8B | +1.7% |
| Operating Income | ¥5.6B | ¥5.4B | +3.3% |
| Ordinary Income | ¥5.8B | ¥5.5B | +4.9% |
| Net Income | ¥2.9B | ¥3.7B | -19.5% |
| ROE | 2.5% | 3.2% | - |
FY2025 Q3 cumulative results show revenue of 155.3B yen (YoY +1.7%), operating income of 5.6B yen (YoY +3.3%), ordinary income of 5.8B yen (YoY +4.9%), and net income of 2.9B yen (YoY -19.5%). The company achieved modest top-line growth and operating profit expansion, but net income declined significantly due to extraordinary losses of 1.3B yen and an effective tax rate of approximately 34.8%. Total assets increased to 171.0B yen from 164.5B yen, while equity rose to 117.1B yen from 113.9B yen, maintaining solid financial health with a debt-to-equity ratio of 0.46 and current ratio of 206.0%.
Revenue increased 2.5B yen (1.7%) to 155.3B yen, driven primarily by the Dispensing Pharmacy segment which grew 249.5M yen to 8.8B yen. The Clinical Testing segment remained essentially flat at 5.9B yen (down 12.2M yen), while the Medical Devices and Maintenance segment expanded to 738.6M yen in external sales (up 84.9M yen from 653.8M yen). The Other segment declined to 66.1M yen from 129.9M yen, reflecting reduced software sales and maintenance revenue. Operating income increased 186M yen (3.3%) despite relatively modest revenue growth, indicating improved cost management. The Clinical Testing segment's operating profit decreased to 219.4M yen from 223.2M yen, while the Dispensing Pharmacy segment's operating profit increased to 615.0M yen from 537.1M yen. The Medical Devices and Maintenance segment's operating loss narrowed to 1.8M yen from 3.3M yen. Corporate expenses increased to 326.1M yen from 318.4M yen. The gap between ordinary income (5.8B yen) and net income (2.9B yen) of 2.9B yen is substantial, representing 50% compression. This is primarily attributable to extraordinary losses of 1.3B yen and an elevated tax burden with an effective tax rate of 34.8%, resulting in income tax expense of approximately 1.6B yen. The pattern represents revenue up/profit down when comparing operating performance to bottom-line results, though operating income itself improved year-over-year.
The Dispensing Pharmacy segment is the core business, accounting for 56.9% of total segment revenue and 73.9% of segment operating profit. Revenue reached 8.8B yen with operating income of 615.0M yen, delivering an operating margin of 7.0%. The Clinical Testing segment generated revenue of 5.9B yen with operating income of 219.4M yen, representing an operating margin of 3.7%, lower than the Dispensing Pharmacy segment. The Medical Devices and Maintenance segment recorded revenue of 1.2B yen (including internal sales) but remained marginally unprofitable with an operating loss of 1.8M yen. The Other segment contributed revenue of 80.0M yen with operating income of 45.5M yen, achieving the highest operating margin at approximately 56.9%, though on a small revenue base. The 4.0 percentage point margin gap between the Clinical Testing (3.7%) and Dispensing Pharmacy (7.0%) segments indicates material profitability differences, with the Dispensing Pharmacy business demonstrating superior operational efficiency.
[Profitability] Operating margin of 3.6% reflects the impact of corporate expenses, while segment-level margins range from 3.7% in Clinical Testing to 7.0% in Dispensing Pharmacy. Net profit margin stands at 1.9%, compressed by extraordinary losses and tax burden. ROE of 2.5% is constrained by the low net profit margin, with DuPont analysis showing net profit margin of 1.9%, asset turnover of 0.908, and financial leverage of 1.46. ROIC of 3.8% indicates below-target capital efficiency. [Cash Quality] Cash and deposits of 34.2B yen provide coverage of 0.95 times short-term debt and current liabilities. Accounts receivable increased to 30.8B yen with DSO extending to approximately 72 days, signaling collection延長. Inventory rose 1.6B yen (29.9%) to 6.9B yen year-over-year. [Investment Efficiency] Asset turnover of 0.908 demonstrates moderate asset utilization. Investment securities increased 1.2B yen (51.6%) to 3.6B yen. [Financial Health] Total equity of 117.1B yen supports a current ratio of 206.0% and quick ratio of 186.9%. Interest-bearing debt of 12.3B yen results in a debt-to-capital ratio of 9.5% and debt-to-equity ratio of 0.46, indicating conservative leverage. Interest coverage ratio of 113.0 reflects strong debt service capacity.
Cash and deposits increased 4.0B yen year-over-year to 34.2B yen, supported by operating profit generation. Working capital expanded as accounts receivable grew 4.9B yen to 30.8B yen and inventories increased 1.6B yen to 6.9B yen, together absorbing approximately 6.5B yen of cash. Accounts payable increased 1.2B yen to 12.5B yen, partially offsetting working capital expansion through extended supplier payment terms. Net working capital stands at 38.4B yen. Total assets expanded 6.5B yen to 171.0B yen, with equity increasing 3.2B yen to 117.1B yen, suggesting net cash generation after accounting for capital expenditures and distributions. Investment securities grew 1.2B yen, indicating deployment of excess cash into financial assets. The company maintains adequate liquidity with cash coverage of short-term liabilities at 0.95 times, though the extension of receivables collection (DSO 72 days) and inventory buildup warrant monitoring for potential working capital efficiency deterioration.
Ordinary income of 5.8B yen versus operating income of 5.6B yen shows non-operating net contribution of approximately 233M yen, comprising primarily financial income. Non-operating income represents 0.15% of revenue, consisting of interest and dividend income and other financial gains. The gap between ordinary income (5.8B yen) and net income (2.9B yen) of 2.9B yen is material, with extraordinary losses of 1.3B yen and income tax expense of approximately 1.6B yen accounting for this compression. The effective tax rate of 34.8% and tax burden coefficient of 0.639 indicate elevated tax impact on earnings. While extraordinary losses are disclosed as non-recurring factors, the absence of operating cash flow data limits assessment of earnings quality through cash conversion. The extension of DSO to 72 days and inventory increase of 29.9% year-over-year raise concerns about the timing and quality of cash realization from reported earnings.
Full-year guidance projects revenue of 206.8B yen (YoY +2.8%), operating income of 7.75B yen (YoY +9.9%), ordinary income of 7.71B yen (YoY +8.9%), and net income of 5.05B yen. Q3 cumulative progress rates are: revenue 75.1%, operating income 72.1%, ordinary income 75.2%, and net income 57.3%. Revenue and ordinary income progress align closely with the standard 75% benchmark for Q3, indicating on-track performance. Operating income progress of 72.1% is slightly below standard, suggesting modest Q4 acceleration is needed. Net income progress of 57.3% is materially below standard, reflecting the impact of Q3 extraordinary losses. The company assumes Q4 net income recovery to approximately 2.2B yen to achieve full-year guidance, implying no recurrence of Q3 extraordinary losses and normalization of the tax rate. The full-year net income guidance of 5.05B yen represents recovery from Q3's 2.9B yen cumulative result, predicated on fourth-quarter operational improvement and absence of additional one-time charges.
Annual dividend of 23.00 yen per share is planned, representing a calculated payout ratio of approximately 33.6% based on full-year net income guidance of 5.05B yen (EPS 162.13 yen) and current Q3 cumulative net income of 2.9B yen. The payout ratio remains within sustainable levels under normal circumstances. No share buyback activity is disclosed. The total return ratio equals the dividend payout ratio of 33.6% in the absence of buyback programs. Dividend sustainability depends on achievement of full-year net income guidance and adequate operating cash flow generation, which cannot be fully assessed without cash flow statement disclosure for the quarterly period.
Working capital management risk: Accounts receivable increased with DSO extending to 72 days while inventory rose 29.9% year-over-year, indicating potential cash conversion delays. If collection periods continue to lengthen or inventory turnover deteriorates further, operating cash generation could be materially impacted, constraining financial flexibility despite current liquidity strength.
Earnings volatility from non-recurring items: Extraordinary losses of 1.3B yen compressed net income by approximately 45% this quarter, with effective tax rate of 34.8% adding further pressure. Recurring exposure to one-time charges or tax rate variability could sustain bottom-line volatility and complicate earnings predictability.
Low profitability and capital efficiency: Operating margin of 3.6%, ROE of 2.5%, and ROIC of 3.8% all indicate below-benchmark performance relative to industry standards. Without margin expansion through pricing power, cost reduction, or business mix improvement, the company faces challenges in generating adequate returns on deployed capital to support growth investments and shareholder returns.
[Industry Position] (Reference - Proprietary Analysis)
The company operates in a healthcare services context with mixed segment exposure including clinical testing, dispensing pharmacy, and medical devices. While not a pure IT/Telecom player, available benchmark data provides directional context. Profitability metrics show material gaps: Operating margin of 3.6% falls significantly below the industry median of 8.0% (IQR: 3.4%-17.4%), positioning the company in the lower quartile. Net profit margin of 1.9% is well below the industry median of 5.6% (IQR: 2.2%-12.0%), indicating substantial room for improvement. ROE of 2.5% materially underperforms the industry median of 8.2% (IQR: 3.5%-13.3%), placing the company in the bottom tier of capital efficiency. ROA of 1.7% (calculated) compares unfavorably to the industry median of 4.2% (IQR: 1.4%-7.0%). Revenue growth of 1.7% lags the industry median of 10.5% (IQR: -1.6%-20.5%), reflecting more mature business dynamics. Financial health indicators are comparatively strong: Equity ratio of approximately 68.5% (implied from financial leverage) exceeds the industry median of 59.5% (IQR: 43.7%-72.8%), indicating conservative capitalization. Current ratio of 206.0% surpasses the industry median of 2.13 (IQR: 1.56-3.58), demonstrating superior liquidity. Operational efficiency shows mixed results: Asset turnover of 0.908 exceeds the industry median of 0.68 (IQR: 0.52-0.95), suggesting relatively efficient asset utilization. Receivables turnover (DSO) of 72 days compares to industry median of 60.5 days (IQR: 46-80 days), indicating slightly slower collection. Overall, the company demonstrates strong financial stability and adequate asset efficiency but faces significant profitability and growth challenges relative to broader industry benchmarks.
※ Industry: IT/Telecom sector (99 companies), Comparison: FY2025 Q3 period, Source: Proprietary analysis
Financial fortress with profitability challenge: The company maintains exceptionally strong financial health metrics including current ratio of 206.0%, debt-to-capital ratio of 9.5%, and interest coverage of 113.0, providing substantial defensive positioning and financial flexibility. However, this financial strength contrasts sharply with weak profitability metrics (operating margin 3.6%, ROE 2.5%, ROIC 3.8%), all materially below industry benchmarks, indicating the company has not effectively deployed its strong balance sheet to generate competitive returns. The key earnings observation is the strategic opportunity to leverage financial capacity for margin-enhancing initiatives.
Bottom-line volatility masks operational stability: While net income declined 19.5% year-over-year due to extraordinary losses of 1.3B yen and elevated tax burden (effective rate 34.8%), operating income grew 3.3% on modest revenue growth of 1.7%, demonstrating underlying operational resilience. The Dispensing Pharmacy segment, representing 57% of revenue and 74% of segment profit, delivered strong performance with operating income increasing to 615M yen from 537M yen. This divergence between operating and net income trends suggests earnings quality assessment should focus on recurring operational performance rather than bottom-line volatility driven by transitory factors.
Working capital dynamics require monitoring: Accounts receivable increased with DSO extending to 72 days while inventory grew 29.9% year-over-year, together absorbing significant cash despite operating profit growth. These working capital trends, if sustained, could constrain cash conversion efficiency and impact the sustainability of the 33.6% dividend payout ratio. The company's full-year guidance implies Q4 net income of approximately 2.2B yen to reach 5.05B yen target, requiring both absence of extraordinary items and improved working capital management to support cash realization of earnings.
This report was automatically generated by AI analyzing XBRL earnings data as an earnings analysis tool. This is not a recommendation to invest in any specific security. Industry benchmarks are reference information compiled from publicly available earnings data. Please make investment decisions at your own responsibility and consult professionals as needed.